| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |